Biopharma venture capital investment fell in Q1, while exit activity — buyouts and IPOs — continued to rise, per a PitchBook report published Wednesday.
Why it matters: Improved exit activity could help restore liquidity after a prolonged slowdown.
Biopharma venture capital investment fell in Q1, while exit activity — buyouts and IPOs — continued to rise, per a PitchBook report published Wednesday.
Why it matters: Improved exit activity could help restore liquidity after a prolonged slowdown.
